Developer docs
API playgroundTry for free, no card

Search company profiles

Genomenon

Full company profile

uuid0000gxs

Namestring
Genomenon
Legal namestring
Genomenon, Inc.
Websiteurl
genomenon.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Genomenon, Inc. is a private, venture-backed genomic intelligence software company founded in 2014 as a spin-out of the University of Michigan and headquartered at 206 E Huron Street in Ann Arbor, Michigan. The company builds AI-driven platforms — Mastermind (germline variants) and the Cancer Knowledgebase / CKB (somatic variants, acquired from The Jackson Laboratory in May 2024) — that read the full text of 11.2 million biomedical articles and 3.7 million supplemental datasets across 18,000 journals to surface gene-variant-disease associations at the variant level. Its three-step pipeline combines automated NLP-based AI reading (Identify), scientist-led structuring of patient-level evidence (Structure), and expert curation (Curate) to deliver traceable, regulatory-grade evidence at scale, with 80% of the clinical exome already curated by 100+ graduate-level scientists.

The company serves two primary enterprise segments: clinical diagnostic laboratories (250+ labs across 145+ countries including Mayo Clinic, Quest Diagnostics, NHS, CDC, Myriad Genetics, and Lurie Children's Hospital), which use Mastermind and CKB to reduce variants of uncertain significance (VUS), accelerate case sign-out, and support ACMG-compliant reporting; and biopharmaceutical companies (75+ precision medicine programs including Loxo@Lilly, Amicus Therapeutics, UCB, Inozyme Pharma, and Mirum Pharmaceuticals), which license custom Real-World Evidence builds to support drug label expansion and regulatory submissions. Revenue is generated through enterprise SaaS subscriptions (Mastermind Professional, CKB FLEX, CKB BOOST) on annual billing, professional services for bespoke evidence builds and clinical diagnostic curation, and a Genetic Disease Sponsorship program; freemium tiers (Mastermind CORE, CKB CORE) serve as product-led growth entry points. Go-to-market blends enterprise field sales, event-driven demand generation across conferences such as ASHG, ACMG, AMP, and Bio-IT World, and an extensive OEM distribution network that embeds Mastermind evidence into Illumina, Agilent, SOPHiA GENETICS, Congenica, and other clinical lab platforms.

Genomenon has raised approximately $29.6M in disclosed equity funding plus ~$3.5M in NIH SBIR grants, with the most recent round a $20M Series B in March 2022 led by Beringea and Spring Mountain Capital and a subsequent $6M SEC-registered offering in May 2024. The company holds a patent on genomic language processing (granted 2019) and has earned industry recognition including Frost & Sullivan's Company of the Year in Genomics (2020) and multiple Bio-IT World Best of Show awards (2019, 2022, 2023). Its CEO is Mike Klein (appointed October 2016), with founder Mark Kiel, MD, PhD serving as Chief Scientific Officer and VP of Product Strategy.

Short descriptiontext

Genomenon is an AI-driven genomic intelligence company that mines 11.2 million biomedical publications to deliver variant-level evidence for clinical diagnostic labs and biopharmaceutical companies pursuing precision medicine, rare disease, and oncology programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersAnn Arbor, United States
HQ citystring
Ann Arbor
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomic variant interpretation, clinical genomics software, biomedical literature curation, real-world evidence builds, cancer genomic databases
Industry4 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAJAN
Knowledge Management & Scientific Collaboration / Literature Intelligence
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code3 codes
  • Software Publishers5132
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Services-Prepackaged Software7372
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Clinical Genomics Software
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model5 records
1Mastermind Software Subscriptions
TypeSubscription Recurring
Description

SaaS subscription model for Mastermind Genomic Intelligence Platform. Offers Professional edition with paid subscription and free CORE tier for limited gene access. Targets clinical diagnostic labs for variant interpretation workflows.

genomenon.com
2CKB Software Subscriptions
TypeSubscription Recurring
Description

Cancer Knowledgebase (CKB) platform subscriptions for clinical labs and healthcare systems. CKB FLEX and CKB CORE product tiers provide somatic variant interpretation capabilities.

genomenon.com
3Custom Real-World Evidence (RWE) Builds for Biopharma
TypeProfessional Services
Description

Bespoke data builds providing variant, patient, and prevalence evidence for pharmaceutical drug development programs. Used for label expansions, trial eligibility, and regulatory submissions. Loxo@Lilly used Genomenon to add 73 variants to the RET label.

genomenon.com
4Genetic Disease Sponsorship
TypeSubscription Recurring
Description

Sponsors fund curation of specific genetic diseases, providing open access to curated evidence while Genomenon expands its database coverage.

genomenon.com
5Clinical Diagnostic Services
TypeProfessional Services
Description

Tailored expert curation services for clinical diagnostic needs, including consulting and bespoke curation projects for healthcare organizations.

genomenon.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details4 tiers
1Mastermind CORE (Free)
ModelFreemiumBilling cadenceOthers
Notes

Free tier providing variant insights for select clinically significant genes. Serves as lead generation and self-serve entry point. No payment information required to sign up.

genomenon.com
2Mastermind Professional (Paid)
ModelSubscriptionBilling cadenceAnnual
Notes

Full-featured subscription tier for clinical lab variant interpretation workflows. Requires institutional email sign-up with paid subscription.

genomenon.com
3CKB CORE (Free)
ModelFreemiumBilling cadenceOthers
Notes

Free oncology gene access covering 50+ oncology genes including 14 new tyrosine kinase genes. Provides evidence-based variant insights.

genomenon.com
4CKB FLEX / BOOST (Enterprise)
ModelSubscriptionBilling cadenceAnnual
Notes

Enterprise-tier somatic variant interpretation platforms for clinical labs and healthcare systems requiring comprehensive cancer genomic profiling.

genomenon.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1Mastermind
Description

AI-powered genomic intelligence platform for variant interpretation - provides literature-driven real-world evidence for clinical diagnostics and precision medicine, covering 11.2 million full-text articles and 3.7 million supplemental datasets

genomenon.com
+3 more records
Core offering1 text field

Genomenon sells AI-driven genomic intelligence software (Mastermind and Cancer Knowledgebase/CKB) that mines 11.2 million full-text biomedical articles and 3.7 million supplemental datasets to surface evidence linking genetic variants to diseases, therapies, and clinical trials. Its 3-step Identify-Structure-Curate workflow combines automated NLP with 100+ scientist curators to produce regulatory-grade variant-level evidence used by clinical diagnostic labs for case sign-out and by biopharma companies for drug label expansion and real-world evidence builds.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Identified 83% more rare disease patients than ChatGPT plus OpenEvidence in head-to-head comparison
+5 more records
Product overview1 text field

Genomenon offers a unified genomic intelligence platform consisting of two core products: Mastermind (for germline variant interpretation) and the Cancer Knowledgebase/CKB (for somatic variant interpretation). These platforms are powered by AI-driven literature mining of over 11.2 million full-text articles and 3.7 million supplemental datasets. The product portfolio includes tiered offerings: Mastermind CORE (free) and Mastermind Professional for clinical labs; CKB CORE (free), CKB BOOST, and CKB FLEX for oncology workflows. Supporting services include Real-World Evidence for biopharma drug development, Genetic Disease Sponsorship for open access to curated evidence, and Clinical Diagnostic Services with expert curation support. The company combines AI with scientist curation to deliver traceable, regulatory-grade evidence at scale.

Product and service6 records
1Mastermind Genomic Intelligence Platform
CategoryClinical Genomics Software
Description

AI-driven genomic search engine that searches millions of biomedical publications to find evidence linking genes, variants, and diseases for clinical diagnosis of cancer and genetic diseases. Provides variant-level evidence, gene-disease associations, and ACMG classification evidence covering 11.2 million full-text articles and 3.7 million supplemental datasets across 18,000 journals.

2Cancer Knowledgebase (CKB)
CategoryClinical Genomics Software
Description

Expert-curated somatic variant database used to interpret cancer genomic profiles, connecting variants to therapies and clinical trials for somatic variant interpretation. Covers germline and somatic variants in oncology workflows.

3Real-World Evidence (RWE) Builds for Biopharma
CategoryProfessional Services
Description

Custom evidence builds providing variant, patient, and prevalence data for drug program decisions, supporting broader labels, trial eligibility, and regulatory submissions for pharmaceutical drug development.

4Genetic Disease Sponsorship
CategoryProfessional Services
Description

Sponsored program providing clinicians and researchers open access to curated genetic evidence for specific diseases, reducing diagnostic barriers while advancing awareness, recognition, and scientific understanding.

5Clinical Diagnostic Services
CategoryProfessional Services
Description

Expert team offering tailored solutions for clinical diagnostic needs, including case review, variant interpretation support, and bespoke curation projects for healthcare organizations.

6Curation On-Demand Service
CategoryProfessional Services
Description

On-demand expert curation service for genetic testing labs when additional support is needed for stalled cases or expert variant interpretation review.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership26 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-10
Description

Strategic sponsorship to improve diagnosis and research for Fabry disease by curating genetic variant data. Collaboration resulted in submission of over 1,300 GLA gene variants to ClinVar, enhancing genetic test interpretation.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2025-09-23
Description

Strategic partnership to transform genomic diagnostics in the U.S. and Japan by integrating genomic data and analysis platforms between Genomenon and Compass Bioinformatics.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2025-09-02
Description

Strategic partnership announced in September 2025 to integrate informatics technologies for clinical labs. Combines Golden Helix's VarSeq and VSWarehouse platforms with Genomenon's Mastermind genomic search engine and CKB cancer knowledgebase.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-07-10
Description

Partnership to advance Thymidine Kinase 2 Deficiency (TK2d) awareness and diagnosis. Collaborated on genetic variant data curation for the TK2 gene, contributing to improved patient outcomes and research.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2025-06-18
Description

Partnership to integrate Genomenon's Cancer Knowledgebase (CKB) somatic data into Intelliseq's iFlow platform to advance somatic variant interpretation capabilities.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-02-07
Description

Partnership to enhance CTX (Cerebrotendinous Xanthomatosis) disease awareness and diagnosis through rare disease data sharing and precision medicine collaboration.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2024-11-07
Description

Partnership to enhance germline variant classification and genomic reporting. GenomOncology offers access to Genomenon's genomic data through its molecular tumor board platform.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2024-11-06
Description

Collaboration to streamline genetic research by integrating Genomenon's genomic literature data with SOPHiA GENETICS' analytics platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-08
Description

Genomenon acquired the Clinical Knowledgebase (CKB) from The Jackson Laboratory in May 2024. The acquisition broadened Genomenon's data scope to include both germline and somatic variants, strengthening its position in genome curation for interpreting cancer genomic profiles.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-05-02
Description

Partnership to advance diagnosis of APDS (Activated Phosphoinositide 3-kinase Delta Syndrome), a rare immunodeficiency syndrome. Democratizing access to genetic evidence for earlier diagnosis.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-27
Description

Genomenon acquired Boston Genetics in June 2023 to accelerate curation of the human genome. The acquisition brought rapid human genome curation capabilities and expanded Genomenon's scientific team.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-02-07
Description

Partnership to advance biomarker discovery and companion diagnostics development, combining Flagship Biosciences' tissue analysis with Genomenon's genomic evidence platform.

13Three Rare Disease Foundations
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-11-29
Description

Partnership with neurodevelopmental disease groups and rare disease foundations including those focused on BPAN, TK2d, and other rare conditions to advance precision drug development through AI/genomics data sharing.

genomenon.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-08-02
Description

Long-standing collaboration on newborn screening by next-generation sequencing. Genomenon curates genes for the BeginNGS newborn screening panel covering 400+ genetic diseases to enable rapid diagnosis and treatment.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2022-06-07
Description

Partnership to improve genomic variant interpretation by integrating Genomenon's Mastermind search engine into Agilent's workflows, accelerated by NVIDIA GPU computing.

16Don't Forget Morgan
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-02-22
Description

Partnership with Don't Forget Morgan rare disease charity to provide new hope for rare disease patients through variant identification and genomic evidence.

genomenon.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-11-11
Description

Partnership to advance genetic diagnosis for rare disease patients with ENPP1 deficiency. Genomenon published the ENPP1 deficiency database and developed genomic evidence supporting Inozyme's clinical programs.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2019-10-15
Description

Mastermind integrated into SOPHiA Platform and Alamut Suite for variant interpretation and genomic analysis.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2019-10-02
Description

Partnership integrating Mastermind into Congenica's clinical platform for genomic variant analysis and diagnosis support.

20BPAN Warriors
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-09-17
Description

Partnership with BPAN Warriors rare disease advocacy organization to find a cure for the ultra-rare neurodegenerative disease BPAN.

genomenon.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-08-06
Description

Keck Graduate Institute launched the Genomics Educators Program with Genomenon to support genomics education and training.

22LifeMap Sciences
TypeTechnology or IntegrationAnnounced on2019-04-02
Description

Partnership integrating Mastermind genomic search engine into GeneCards Suite and TGex platform for genomic research and analysis.

genomenon.com
23Shanghai Shanyi
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-08-20
Description

Strategic partnership to bring Genomenon's leading genomic search engine to the China market through local distribution.

genomenon.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-07-31
Description

Partnership to offer evidence-based genomic panel design services combining Fluidigm's technology with Genomenon's literature-derived variant evidence.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-06-26
Description

University of Vermont Health Network standardized on Genomenon's Mastermind genomic search engine for clinical variant interpretation.

26Swift Biosciences
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-05-23
Description

Partnership to accelerate biomarker selection for targeted NGS panels using Genomenon's literature evidence and Swift Biosciences' sequencing technology.

genomenon.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical genomics interpretation platform with AI-driven variant analysis and a broad customer base across hospitals and labs. Directly comparable to Genomenon's Mastermind and Alamut-integrated clinical lab offering, and an existing partner.

TypeDirect peer
Description

Clinical genomic variant interpretation platform used by clinical labs for rare disease and cancer diagnostics. Directly comparable to Genomenon's clinical lab workflow and an existing Mastermind integration partner.

TypeDirect peer
Description

Clinical genomics interpretation platform for hereditary disease and oncology. Directly comparable to Genomenon's clinical lab offering and an existing integration partner.

TypeDirect peer
Description

Clinical genomics software (VarSeq, VSWarehouse) for NGS variant annotation and clinical reporting. Directly comparable to Genomenon's clinical lab segment, and recently announced a strategic partnership integrating Mastermind.

TypeBroad incumbent
Description

Dominant NGS sequencing platform vendor that also offers DRAGEN secondary analysis and clinical informatics. A broad incumbent with overlapping capabilities in clinical genomics interpretation, and a current Genomenon partner/integrator.

TypeBroad incumbent
Description

Large bioinformatics vendor offering QCI Interpret for clinical variant interpretation and evidence curation. A broad incumbent serving the same clinical lab and biopharma customers as Genomenon.

7DNASTAR
TypeDirect peer
Description

Genomic sequence analysis software used in research and clinical labs. Comparable to Genomenon's variant interpretation offering and an existing Mastermind integration partner.

TypeBroad incumbent
Description

Major life sciences instrumentation and genomics software vendor. Comparable as a partner/integrator in clinical genomics workflows and a current Genomenon partner integrating Mastermind with Agilent platforms.

TypeEmerging player
Description

Molecular tumor board and oncology genomic reporting platform. Comparable to Genomenon's CKB offerings in somatic interpretation and an existing technology integration partner.

10PierianDx (nference)
TypeEmerging player
Description

Clinical genomics informatics platform supporting variant interpretation and reporting. Comparable to Genomenon's clinical lab interpretation offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration21 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genomenon

Clinical Genomics Softwaregenomenon.com

Genomenon is an AI-driven genomic intelligence company that mines 11.2 million biomedical publications to deliver variant-level evidence for clinical diagnostic labs and biopharmaceutical companies pursuing precision medicine, rare disease, and oncology programs.

What Genomenon does

Genomenon, Inc. is a private, venture-backed genomic intelligence software company founded in 2014 as a spin-out of the University of Michigan and headquartered at 206 E Huron Street in Ann Arbor, Michigan. The company builds AI-driven platforms — Mastermind (germline variants) and the Cancer Knowledgebase / CKB (somatic variants, acquired from The Jackson Laboratory in May 2024) — that read the full text of 11.2 million biomedical articles and 3.7 million supplemental datasets across 18,000 journals to surface gene-variant-disease associations at the variant level. Its three-step pipeline combines automated NLP-based AI reading (Identify), scientist-led structuring of patient-level evidence (Structure), and expert curation (Curate) to deliver traceable, regulatory-grade evidence at scale, with 80% of the clinical exome already curated by 100+ graduate-level scientists.

The company serves two primary enterprise segments: clinical diagnostic laboratories (250+ labs across 145+ countries including Mayo Clinic, Quest Diagnostics, NHS, CDC, Myriad Genetics, and Lurie Children's Hospital), which use Mastermind and CKB to reduce variants of uncertain significance (VUS), accelerate case sign-out, and support ACMG-compliant reporting; and biopharmaceutical companies (75+ precision medicine programs including Loxo@Lilly, Amicus Therapeutics, UCB, Inozyme Pharma, and Mirum Pharmaceuticals), which license custom Real-World Evidence builds to support drug label expansion and regulatory submissions. Revenue is generated through enterprise SaaS subscriptions (Mastermind Professional, CKB FLEX, CKB BOOST) on annual billing, professional services for bespoke evidence builds and clinical diagnostic curation, and a Genetic Disease Sponsorship program; freemium tiers (Mastermind CORE, CKB CORE) serve as product-led growth entry points. Go-to-market blends enterprise field sales, event-driven demand generation across conferences such as ASHG, ACMG, AMP, and Bio-IT World, and an extensive OEM distribution network that embeds Mastermind evidence into Illumina, Agilent, SOPHiA GENETICS, Congenica, and other clinical lab platforms.

Genomenon has raised approximately $29.6M in disclosed equity funding plus ~$3.5M in NIH SBIR grants, with the most recent round a $20M Series B in March 2022 led by Beringea and Spring Mountain Capital and a subsequent $6M SEC-registered offering in May 2024. The company holds a patent on genomic language processing (granted 2019) and has earned industry recognition including Frost & Sullivan's Company of the Year in Genomics (2020) and multiple Bio-IT World Best of Show awards (2019, 2022, 2023). Its CEO is Mike Klein (appointed October 2016), with founder Mark Kiel, MD, PhD serving as Chief Scientific Officer and VP of Product Strategy.

Genomenon firmographics

Firmographics
Name
Genomenon
Legal name
Genomenon, Inc.
Website
https://genomenon.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
Genomenon is an AI-driven genomic intelligence company that mines 11.2 million biomedical publications to deliver variant-level evidence for clinical diagnostic labs and biopharmaceutical companies pursuing precision medicine, rare disease, and oncology programs.
Ownership category
akta.pro rank

Genomenon industry classification

Industry
Product category
Clinical Genomics Software
NAICS
Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAJAN
Knowledge Management & Scientific Collaboration / Literature Intelligence
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Genomic variant interpretation
  • Clinical genomics software
  • Biomedical literature curation
  • Real-world evidence builds
  • Cancer genomic databases

Where Genomenon is headquartered

Location

Headquarters

HQ city
Ann Arbor
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Genomenon business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Mastermind Software Subscriptions: SaaS subscription model for Mastermind Genomic Intelligence Platform. Offers Professional edition with paid subscription and free CORE tier for limited gene access. Targets clinical diagnostic labs for variant interpretation workflows.
  2. CKB Software Subscriptions: Cancer Knowledgebase (CKB) platform subscriptions for clinical labs and healthcare systems. CKB FLEX and CKB CORE product tiers provide somatic variant interpretation capabilities.
  3. Custom Real-World Evidence (RWE) Builds for Biopharma: Bespoke data builds providing variant, patient, and prevalence evidence for pharmaceutical drug development programs. Used for label expansions, trial eligibility, and regulatory submissions. Loxo@Lilly used Genomenon to add 73 variants to the RET label.
  4. Genetic Disease Sponsorship: Sponsors fund curation of specific genetic diseases, providing open access to curated evidence while Genomenon expands its database coverage.
  5. Clinical Diagnostic Services: Tailored expert curation services for clinical diagnostic needs, including consulting and bespoke curation projects for healthcare organizations.

Pricing tiers

ModelBillingPrice
FreemiumOthersMastermind CORE (Free)
SubscriptionAnnualMastermind Professional (Paid)
FreemiumOthersCKB CORE (Free)
SubscriptionAnnualCKB FLEX / BOOST (Enterprise)

Go-to-market motion4 records

Distribution channels3 records

Marketing channels7 records

Genomenon product offering

Product offering

Core offering

Genomenon sells AI-driven genomic intelligence software (Mastermind and Cancer Knowledgebase/CKB) that mines 11.2 million full-text biomedical articles and 3.7 million supplemental datasets to surface evidence linking genetic variants to diseases, therapies, and clinical trials. Its 3-step Identify-Structure-Curate workflow combines automated NLP with 100+ scientist curators to produce regulatory-grade variant-level evidence used by clinical diagnostic labs for case sign-out and by biopharma companies for drug label expansion and real-world evidence builds.

Product overview

Genomenon offers a unified genomic intelligence platform consisting of two core products: Mastermind (for germline variant interpretation) and the Cancer Knowledgebase/CKB (for somatic variant interpretation). These platforms are powered by AI-driven literature mining of over 11.2 million full-text articles and 3.7 million supplemental datasets. The product portfolio includes tiered offerings: Mastermind CORE (free) and Mastermind Professional for clinical labs; CKB CORE (free), CKB BOOST, and CKB FLEX for oncology workflows. Supporting services include Real-World Evidence for biopharma drug development, Genetic Disease Sponsorship for open access to curated evidence, and Clinical Diagnostic Services with expert curation support. The company combines AI with scientist curation to deliver traceable, regulatory-grade evidence at scale.

Differentiator

Problem solved

Functional benefit

Brands

  • Mastermind: AI-powered genomic intelligence platform for variant interpretation - provides literature-driven real-world evidence for clinical diagnostics and precision medicine, covering 11.2 million full-text articles and 3.7 million supplemental datasets
  • CKB (Cancer Knowledgebase)
  • Mastermind CORE
  • CKB CORE

Products and services

  • Mastermind Genomic Intelligence Platform AI-driven genomic search engine that searches millions of biomedical publications to find evidence linking genes, variants, and diseases for clinical diagnosis of cancer and genetic diseases. Provides variant-level evidence, gene-disease associations, and ACMG classification evidence covering 11.2 million full-text articles and 3.7 million supplemental datasets across 18,000 journals.
  • Cancer Knowledgebase (CKB) Expert-curated somatic variant database used to interpret cancer genomic profiles, connecting variants to therapies and clinical trials for somatic variant interpretation. Covers germline and somatic variants in oncology workflows.
  • Real-World Evidence (RWE) Builds for Biopharma Custom evidence builds providing variant, patient, and prevalence data for drug program decisions, supporting broader labels, trial eligibility, and regulatory submissions for pharmaceutical drug development.
  • Genetic Disease Sponsorship Sponsored program providing clinicians and researchers open access to curated genetic evidence for specific diseases, reducing diagnostic barriers while advancing awareness, recognition, and scientific understanding.
  • Clinical Diagnostic Services Expert team offering tailored solutions for clinical diagnostic needs, including case review, variant interpretation support, and bespoke curation projects for healthcare organizations.
  • Curation On-Demand Service On-demand expert curation service for genetic testing labs when additional support is needed for stalled cases or expert variant interpretation review.

Quantifiable outcome

  • Identified 83% more rare disease patients than ChatGPT plus OpenEvidence in head-to-head comparison
  • +5 more outcomes

Companies that use Genomenon

Customer profile

Named customers14 records

Segments3 records

Ideal customer profiles3 records

Genomenon technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration21 records

AI capability6 records

Feature7 records

Genomenon partnerships and signals

Strategic signal

Partnerships

26 partnerships are on record, tiered major, core and minor.

  • Amicus TherapeuticsmajorStrategic or Co-development Partner · 10 March 2026Strategic sponsorship to improve diagnosis and research for Fabry disease by curating genetic variant data. Collaboration resulted in submission of over 1,300 GLA gene variants to ClinVar, enhancing genetic test interpretation.
  • Compass BioinformaticsmajorTechnology or Integration · 23 September 2025Strategic partnership to transform genomic diagnostics in the U.S. and Japan by integrating genomic data and analysis platforms between Genomenon and Compass Bioinformatics.
  • Golden HelixmajorTechnology or Integration · 2 September 2025Strategic partnership announced in September 2025 to integrate informatics technologies for clinical labs. Combines Golden Helix's VarSeq and VSWarehouse platforms with Genomenon's Mastermind genomic search engine and CKB cancer knowledgebase.
  • UCBmajorStrategic or Co-development Partner · 10 July 2025Partnership to advance Thymidine Kinase 2 Deficiency (TK2d) awareness and diagnosis. Collaborated on genetic variant data curation for the TK2 gene, contributing to improved patient outcomes and research.
  • IntelliseqmajorTechnology or Integration · 18 June 2025Partnership to integrate Genomenon's Cancer Knowledgebase (CKB) somatic data into Intelliseq's iFlow platform to advance somatic variant interpretation capabilities.
  • Mirum PharmaceuticalsmajorStrategic or Co-development Partner · 7 February 2025Partnership to enhance CTX (Cerebrotendinous Xanthomatosis) disease awareness and diagnosis through rare disease data sharing and precision medicine collaboration.
  • GenomOncologymajorTechnology or Integration · 7 November 2024Partnership to enhance germline variant classification and genomic reporting. GenomOncology offers access to Genomenon's genomic data through its molecular tumor board platform.
  • SOPHiA GENETICSmajorTechnology or Integration · 6 November 2024Collaboration to streamline genetic research by integrating Genomenon's genomic literature data with SOPHiA GENETICS' analytics platform.
  • The Jackson Laboratory (JAX)coreStrategic or Co-development Partner · 8 May 2024Genomenon acquired the Clinical Knowledgebase (CKB) from The Jackson Laboratory in May 2024. The acquisition broadened Genomenon's data scope to include both germline and somatic variants, strengthening its position in genome curation for interpreting cancer genomic profiles.
  • PharmingmajorStrategic or Co-development Partner · 2 May 2024Partnership to advance diagnosis of APDS (Activated Phosphoinositide 3-kinase Delta Syndrome), a rare immunodeficiency syndrome. Democratizing access to genetic evidence for earlier diagnosis.
  • Boston GeneticscoreStrategic or Co-development Partner · 27 June 2023Genomenon acquired Boston Genetics in June 2023 to accelerate curation of the human genome. The acquisition brought rapid human genome curation capabilities and expanded Genomenon's scientific team.
  • Flagship BiosciencesmajorStrategic or Co-development Partner · 7 February 2023Partnership to advance biomarker discovery and companion diagnostics development, combining Flagship Biosciences' tissue analysis with Genomenon's genomic evidence platform.
  • Three Rare Disease FoundationsmajorStrategic or Co-development Partner · 29 November 2022Partnership with neurodevelopmental disease groups and rare disease foundations including those focused on BPAN, TK2d, and other rare conditions to advance precision drug development through AI/genomics data sharing.
  • Rady Children's Institute for Genomic MedicinemajorStrategic or Co-development Partner · 2 August 2022Long-standing collaboration on newborn screening by next-generation sequencing. Genomenon curates genes for the BeginNGS newborn screening panel covering 400+ genetic diseases to enable rapid diagnosis and treatment.
  • AgilentmajorTechnology or Integration · 7 June 2022Partnership to improve genomic variant interpretation by integrating Genomenon's Mastermind search engine into Agilent's workflows, accelerated by NVIDIA GPU computing.
  • Don't Forget MorganminorStrategic or Co-development Partner · 22 February 2022Partnership with Don't Forget Morgan rare disease charity to provide new hope for rare disease patients through variant identification and genomic evidence.
  • Inozyme PharmamajorStrategic or Co-development Partner · 11 November 2021Partnership to advance genetic diagnosis for rare disease patients with ENPP1 deficiency. Genomenon published the ENPP1 deficiency database and developed genomic evidence supporting Inozyme's clinical programs.
  • SOPHiA GENETICSmajorTechnology or Integration · 15 October 2019Mastermind integrated into SOPHiA Platform and Alamut Suite for variant interpretation and genomic analysis.
  • CongenicamajorTechnology or Integration · 2 October 2019Partnership integrating Mastermind into Congenica's clinical platform for genomic variant analysis and diagnosis support.
  • BPAN WarriorsminorStrategic or Co-development Partner · 17 September 2019Partnership with BPAN Warriors rare disease advocacy organization to find a cure for the ultra-rare neurodegenerative disease BPAN.
  • Keck Graduate InstituteminorStrategic or Co-development Partner · 6 August 2019Keck Graduate Institute launched the Genomics Educators Program with Genomenon to support genomics education and training.
  • LifeMap SciencesTechnology or Integration · 2 April 2019Partnership integrating Mastermind genomic search engine into GeneCards Suite and TGex platform for genomic research and analysis.
  • Shanghai ShanyiminorChannel Partner/ Reseller/ Distributor · 20 August 2018Strategic partnership to bring Genomenon's leading genomic search engine to the China market through local distribution.
  • FluidigmminorStrategic or Co-development Partner · 31 July 2018Partnership to offer evidence-based genomic panel design services combining Fluidigm's technology with Genomenon's literature-derived variant evidence.
  • University of Vermont Health NetworkminorStrategic or Co-development Partner · 26 June 2018University of Vermont Health Network standardized on Genomenon's Mastermind genomic search engine for clinical variant interpretation.
  • Swift BiosciencesminorStrategic or Co-development Partner · 23 May 2018Partnership to accelerate biomarker selection for targeted NGS panels using Genomenon's literature evidence and Swift Biosciences' sequencing technology.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Genomenon competitors and assessment

Company assessment

Direct peers

  • SOPHiA GENETICS: Clinical genomics interpretation platform with AI-driven variant analysis and a broad customer base across hospitals and labs. Directly comparable to Genomenon's Mastermind and Alamut-integrated clinical lab offering, and an existing partner.
  • Congenica: Clinical genomic variant interpretation platform used by clinical labs for rare disease and cancer diagnostics. Directly comparable to Genomenon's clinical lab workflow and an existing Mastermind integration partner.
  • Fabric Genomics (Fabric Health): Clinical genomics interpretation platform for hereditary disease and oncology. Directly comparable to Genomenon's clinical lab offering and an existing integration partner.
  • Golden Helix: Clinical genomics software (VarSeq, VSWarehouse) for NGS variant annotation and clinical reporting. Directly comparable to Genomenon's clinical lab segment, and recently announced a strategic partnership integrating Mastermind.
  • DNASTAR: Genomic sequence analysis software used in research and clinical labs. Comparable to Genomenon's variant interpretation offering and an existing Mastermind integration partner.

Broad incumbents

  • Illumina: Dominant NGS sequencing platform vendor that also offers DRAGEN secondary analysis and clinical informatics. A broad incumbent with overlapping capabilities in clinical genomics interpretation, and a current Genomenon partner/integrator.
  • QIAGEN (QCI / QIAGEN Clinical Insight): Large bioinformatics vendor offering QCI Interpret for clinical variant interpretation and evidence curation. A broad incumbent serving the same clinical lab and biopharma customers as Genomenon.
  • Agilent Technologies: Major life sciences instrumentation and genomics software vendor. Comparable as a partner/integrator in clinical genomics workflows and a current Genomenon partner integrating Mastermind with Agilent platforms.

Emerging players

  • GenomOncology: Molecular tumor board and oncology genomic reporting platform. Comparable to Genomenon's CKB offerings in somatic interpretation and an existing technology integration partner.
  • PierianDx (nference): Clinical genomics informatics platform supporting variant interpretation and reporting. Comparable to Genomenon's clinical lab interpretation offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Genomenon social profiles

Digital presence

Genomenon compliance and trust

Trust signal

Compliance4 records

Genomenon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genomenon leadership team

Management profile

Number of profiles

Profiles8 records

Genomenon subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Genomenon funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genomenon M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genomenon

What does Genomenon do?

Genomenon sells AI-driven genomic intelligence software (Mastermind and Cancer Knowledgebase/CKB) that mines 11.2 million full-text biomedical articles and 3.7 million supplemental datasets to surface evidence linking genetic variants to diseases, therapies, and clinical trials. Its 3-step Identify-Structure-Curate workflow combines automated NLP with 100+ scientist curators to produce regulatory-grade variant-level evidence used by clinical diagnostic labs for case sign-out and by biopharma companies for drug label expansion and real-world evidence builds.

Is Genomenon a public or private company?

Genomenon is a private company. It is classified as venture growth investor backed and is currently operating.

When was Genomenon founded?

Genomenon was founded in 2014. It employs 101 to 250 people.

Where is Genomenon based?

Genomenon is headquartered in Ann Arbor, United States, in the North America region.

How does Genomenon make money?

Five revenue lines are on record. Mastermind Software Subscriptions are the primary driver. The others are CKB Software Subscriptions, custom Real-World Evidence (RWE) Builds for Biopharma, genetic Disease Sponsorship and clinical Diagnostic Services.

Who are Genomenon's main competitors?

Direct peers on record are SOPHiA GENETICS, Congenica, Fabric Genomics (Fabric Health), Golden Helix and DNASTAR. Broad incumbents are Illumina, QIAGEN (QCI / QIAGEN Clinical Insight) and Agilent Technologies. Emerging players are GenomOncology and PierianDx (nference).

Does Genomenon have an API?

No public API is recorded for Genomenon.

What industry is Genomenon in?

Genomenon's product category is Clinical Genomics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comCompetitive Landscape: Key Market Leaders and New Entrants in the Somatic Genetic Testing SectorThe Business Research Company released a market report projecting the somatic genetic testing sector will reach $14.92 billion by 2030, driven by next-generation sequencing and precision medicine adoption. The article highlights strategic activities including Genomenon Inc.'s acquisition of Boston Genetics Inc. to enhance genomic interpretation capabilities and Strand Life Sciences' launch of a new liquid biopsy test in India.openPR.comOverview of Segmentation, Market Dynamics, and Competitive Landscape in the Pharmacogenomics MarketThe pharmacogenomics market is projected to reach $15.98 billion by 2030, growing at a 10.2% CAGR, driven by precision medicine funding, AI-powered genomic analysis, and expanded applications in oncology and cardiology. In June 2023, Genomenon acquired Boston Genetics to combine its AI-driven genomic platform with Boston Genetics' genetic science expertise for clinical diagnostics and pharmaceutical development. In December 2024, PGxAI launched its Sirius AI model, which personalizes drug selection and dosage based on a patient's genome, covering 730 drugs and 40 pharmacogenes.PR NewswireGenomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and DiagnosisGenomenon announced a strategic sponsorship from Amicus Therapeutics to accelerate Fabry disease diagnosis through AI-driven curation and classification of GLA gene variants. The collaboration submitted over 1,300 GLA variants to ClinVar, including more than 1,000 classified as pathogenic or likely pathogenic, with over 50% not previously in the database. This partnership aims to expand publicly available genetic evidence to reduce diagnostic delays for patients with this rare lysosomal storage disorder.HrtodayErin McCann elevated to Chief People Officer at GenomenonGenomenon elevated Erin McCann to Chief People Officer, having previously served as Head of People since March 2024. She will oversee people and culture strategy as the company grows in biotech and precision medicine. Her leadership contributed to Genomenon being named a Best Place to Work in 2024 and 2025.PR NewswireGenomenon and Compass Bioinformatics Partner to Transform Genomic Diagnostics in the U.S. and JapanGenomenon, a genomic intelligence company based in Ann Arbor, Michigan, announced a strategic partnership with Compass Bioinformatics to integrate its Mastermind FLEX Data into Compass's InheriNext platform for genetic disease diagnostics. The collaboration combines Genomenon's curated gene and variant-level content with Compass's AI-powered genomic analysis, enhancing variant interpretation for clinicians and researchers. The partnership expands Genomenon's presence in Japan and Asia while strengthening InheriNext for U.S. users, with the platform already deployed in over 40 leading rare disease research and diagnostic institutes in Japan.YahooGenomenon and Compass Bioinformatics Partner to Transform Genomic Diagnostics in the U.S. and JapanGenomenon and Compass Bioinformatics announced a partnership integrating Genomenon's Mastermind FLEX Data into Compass's InheriNext platform for genetic disease diagnostics. The integration strengthens variant interpretation with ACMG-guided evidence and expands Genomenon's presence in Japan and Asia. InheriNext has been deployed in over 40 institutes in Japan.GenomenonGenomenon and Compass Bioinformatics Partner to Transform Genomic Diagnostics in the U.S. and JapanGenomenon and Compass Bioinformatics announced a strategic partnership to integrate Genomenon’s Mastermind FLEX Data into Compass Bioinformatics’ InheriNext platform for genetic disease diagnostics. This collaboration aims to enhance variant interpretation capabilities for clinicians in the U.S. and Japan while expanding Genomenon’s market presence in Asia.PR NewswireGolden Helix and Genomenon Announce Strategic Partnership to Advance Clinical DiagnosticsGolden Helix and Genomenon announced a partnership to integrate Genomenon's Mastermind Genomic Intelligence Platform and Cancer Knowledgebase into Golden Helix's VarSeq software suite. The integration provides curated germline and somatic content for variant interpretation, harmonized with public databases like ClinVar. The collaboration aims to reduce manual curation time and accelerate clinical decision-making.GenomenonGenomic Evidence at the Gene and Variant LevelGenomenon is enhancing its Cancer Knowledgebase and offering access to a vast database of genomic information, including over 27 million variants. Their platforms aim to simplify complex genetic data into actionable insights for patient diagnosis and precision medicine development. The company is also set to showcase AI-powered literature-based real-world evidence at the upcoming AMP 2025 Annual Meeting & Expo.AnnarborusaAngel Investing Plays a Critical Role in Tech StartupsAnn Arbor SPARK and the Michigan Angel Fund are actively facilitating early-stage angel investing to support high-growth tech startups in Michigan, filling a funding gap before venture capital becomes available. The article highlights success stories like Genomenon and SkySpecs, which utilized this early capital to become market leaders, while also outlining various support programs such as bootcamps and grants.